• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Additional Reimbursement Considerations in Oncology

Video

During this discussion, Scott Gottlieb, MD; Michael Kolodziej, MD; and Ted Okon, MBA, further discuss how various reimbursement models are impacting clinical practice in oncology.

Dr Gottlieb begins by explaining why the CMS stepped in to regulate the practice of medicine by implementing additional rules regarding the provision of oncology products.

Healthcare reform has impacted oncology care in the United States in many ways, including the establishment of oncology medical homes and the implementation of payment reform models, remarks Mr Okon. He also describes differences in drug pricing in the community setting versus the hospital setting, and discusses the so-called drug incentive.

When establishing measures to help improve current healthcare models, various stakeholders should collaborate and discuss opportunities for achieving optimal efficiency, suggests Mr Okon. Stakeholders also need to work together to improve the reimbursement model for oncology services.


Related Videos
Screenshot of Fran Gregory, PharmD, MBA, during a video interview
Video 13 - "Individualized Therapy for Specific Infections Associated with Bronchiectasis"
Michael Morse, MD, Duke University Cancer Center
Amit Singal, MD, UT Southwestern Medical Center
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Beau Raymond, MD
Dr Sophia Humphreys
Video 15 - "Ensuring Fair Cardiovascular Care for All: Concluding Perspectives on Disparities and Inclusion"
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.